The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies (Q34786560)

4 August 2017

1 reference

title

The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies (English)

1 reference

4 August 2017

0 references

Artur Beltrame Ribeiro

series ordinal

object named as

Artur B Ribeiro

1 reference

ORCID Public Data File 2021

4 August 2017

1 reference

author name string

Maria-Teresa Zanella

series ordinal

1 reference

4 August 2017

language of work or name

1 reference

1 July 2002

1 reference

4 August 2017

published in

Clinical Therapeutics

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

1019-1034

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Diabetes trends in the U.S.: 1990-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Effective Antihypertensive Treatment Postpones Renal Insufficiency in Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Effect of proteinuria on mortality in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Renoprotective therapy: titration against urinary protein excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Predicting diabetic nephropathy in insulin-dependent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Losartan as an alternative to ACE inhibitors in patients with renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Diabetic nephropathy: prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Nephropathy and coronary death--the fatal twins in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Diabetes, hypertension, and cardiovascular disease: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Plasma renin activity and hypertension in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Renal responses to AT1 receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Glomerular permselectivity in early stages of overt diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Angiotensin II-forming pathways in normal and failing human hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Inadequate aldosterone response to hyperkalemia during angiotensin converting enzyme inhibition in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Prevention of diabetic renal disease with special reference to microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

Effect of blood glucose on left ventricular mass in patients with hypertension and type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980016-9

7 January 2021

10.1016/S0149-2918(02)80016-9

Identifiers

DOI

1 reference

4 August 2017

1 reference